Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial. (nature.com)

Authors: Hoeijmakers LL … Blank CU Journal: Nature Medicine Published: 2026-03-01 DOI: https://doi.org/10.1038/s41591-025-04158-9